Diabetes & Metabolism Journal.2017;41(4):322-323. doi:10.4093/dmj.2017.41.4.322
Diabetes & Metabolism Journal
to Present ISSN: 2233-6079
Sort by
DISPLAY OPTIONS
Format:
Per page:
Diabetes & Metabolism Journal.2017;41(4):316-321. doi:10.4093/dmj.2017.41.4.316
BACKGROUND: The association of chronic hepatitis C virus (HCV) infection with type 2 diabetes mellitus (T2DM) was first reported in 1994. Little is known about the effect of direct-acting antiviral agents (DAAs) on glycemic control in T2DM patients. The aim of the present study was to evaluate the factors associated with improved glycemic control (IGC) by DAA treatment in Egyptian T2DM patients with chronic HCV genotype 4 infection. METHODS: This study included 460 T2DM patients with chronic HCV genotype 4 infection. Four hundred patients received DAAs and 60 patients did not receive DAAs. Patients with sustained virological response after 3 months of DAAs (378 patients) were allocated into two groups: first group included 292 patients (77.2%) with IGC and second group included 86 patients (22.8%) with non-improved glycemic control (NIGC). RESULTS: In IGC group, 78 patients (26.7%) needed to decrease the dose of antidiabetic treatment. There were no significant differences between IGC and NIGC groups as regards age, sex, and body mass index. The percentage of patients with positive family history of T2DM, those with Child B class and duration of T2DM were significantly higher in NIGC group compared to IGC. CONCLUSION: Diabetic patients receiving DAAs should be closely monitored for reduction of antidiabetic drugs especially insulin and sulfonylurea to avoid hypoglycemic events. Improvement of glycemic control with DAAs is more in patients without family history of T2DM, short duration of diabetes mellitus, and mild liver disease.
Antiviral Agents ; Body Mass Index ; Child ; Diabetes Mellitus ; Diabetes Mellitus, Type 2* ; Genotype ; Hepacivirus ; Hepatitis C, Chronic* ; Hepatitis, Chronic* ; Humans ; Hypoglycemic Agents ; Insulin ; Liver Diseases
Antiviral Agents ; Body Mass Index ; Child ; Diabetes Mellitus ; Diabetes Mellitus, Type 2* ; Genotype ; Hepacivirus ; Hepatitis C, Chronic* ; Hepatitis, Chronic* ; Humans ; Hypoglycemic Agents ; Insulin ; Liver Diseases
Diabetes & Metabolism Journal.2017;41(4):303-315. doi:10.4093/dmj.2017.41.4.303
BACKGROUND: The increase in circulating free fatty acid (FFA) levels is a major factor that induces malfunction in pancreatic β-cells. We evaluated the effect of FFAs reconstituted according to the profile of circulating fatty acids found in obese adolescents on the viability and function of the murine insulinoma cell line (mouse insulinoma [MIN6]). METHODS: From fatty acids obtained commercially, plasma-FFA profiles of three different youth populations were reconstituted: obese with metabolic syndrome; obese without metabolic syndrome; and normal weight without metabolic syndrome. MIN6 cells were treated for 24 or 48 hours with the three FFA profiles, and glucose-stimulated insulin secretion, cell viability, mitochondrial function and antioxidant activity were evaluated. RESULTS: The high FFA content and high polyunsaturated ω6/ω3 ratio, present in plasma of obese adolescents with metabolic syndrome had a toxic effect on MIN6 cell viability and function, increasing oxidative stress and decreasing glucose-dependent insulin secretion. CONCLUSION: These results could help to guide nutritional management of obese young individuals, encouraging the increase of ω-3-rich food consumption in order to reduce the likelihood of deterioration of β-cells and the possible development of type 2 diabetes mellitus.
Adolescent* ; Cell Line ; Cell Survival ; Diabetes Mellitus, Type 2 ; Fatty Acids* ; Fatty Acids, Nonesterified ; Humans ; In Vitro Techniques* ; Insulin ; Insulin-Secreting Cells ; Insulinoma ; Obesity ; Oxidative Stress ; Plasma*
Adolescent* ; Cell Line ; Cell Survival ; Diabetes Mellitus, Type 2 ; Fatty Acids* ; Fatty Acids, Nonesterified ; Humans ; In Vitro Techniques* ; Insulin ; Insulin-Secreting Cells ; Insulinoma ; Obesity ; Oxidative Stress ; Plasma*
Diabetes & Metabolism Journal.2017;41(4):296-302. doi:10.4093/dmj.2017.41.4.296
BACKGROUND: Previous reports have demonstrated a bidirectional relationship between depression and diabetes mellitus (DM), accentuating a need for more intensive depression screening in DM patients. There is a relative paucity of data on the mortality of depressed DM patients in Korea. METHODS: Retrospective data from January 2003 to December 2013 were collected for adult type 2 diabetes mellitus (T2DM) patients older than 30 years using the National Health Information database maintained by the Korean National Health Insurance Service (NHIS). Demographic characteristics were analyzed with descriptive statistics, and the annual prevalence of depression was estimated. Mortality rates and hazard ratios for each age group (stratified into six age groups) of patients diagnosed with T2DM in 2003 were estimated using a Cox proportional hazard method, with the Kaplan-Meier cumulative survival curve showing the overall survival rates according to the T2DM status until the given year of 2013. RESULTS: The annual prevalence of depression was consistently higher in T2DM group from 2003 to 2013. The mortality hazard ratio was higher in the depressed in all age groups, and the risk was higher in male groups and in younger-aged groups. CONCLUSION: Depression was significantly associated with a high mortality risk in T2DM patients; hence, a more systematic surveillance of T2DM patients to identify risk factors for depression might contribute significantly to reducing mortality risk in this group of patients.
Adult ; Cohort Studies* ; Depression* ; Diabetes Mellitus ; Diabetes Mellitus, Type 2* ; Humans ; Korea ; Male ; Mass Screening ; Methods ; Mortality* ; National Health Programs ; Prevalence ; Prognosis ; Retrospective Studies ; Risk Factors ; Survival Rate
Adult ; Cohort Studies* ; Depression* ; Diabetes Mellitus ; Diabetes Mellitus, Type 2* ; Humans ; Korea ; Male ; Mass Screening ; Methods ; Mortality* ; National Health Programs ; Prevalence ; Prognosis ; Retrospective Studies ; Risk Factors ; Survival Rate
Determinants of Long-Term Durable Glycemic Control in New-Onset Type 2 Diabetes Mellitus.
Diabetes & Metabolism Journal.2017;41(4):284-295. doi:10.4093/dmj.2017.41.4.284
BACKGROUND: Long-term durable glycemic control is a difficult goal in the management of type 2 diabetes mellitus (T2DM). We evaluated the factors associated with durable glycemic control in a real clinical setting. METHODS: We retrospectively reviewed the medical records of 194 new-onset, drug-naïve patients with T2DM who were diagnosed between January 2011 and March 2013, and were followed up for >2 years. Glycemic durability was defined as the maintenance of optimal glycemic control (glycosylated hemoglobin [HbA1c] <7.0%) for 2 years without substitution or adding other glucose-lowering agents. Clinical factors and glycemic markers associated with glycemic durability were compared between two groups: a durability group and a non-durability group. RESULTS: Patients in the durability group had a higher baseline body mass index (26.1 kg/m² vs. 24.9 kg/m²) and lower HbA1c (8.6% vs. 9.7%) than the non-durability group. The initial choice of glucose-lowering agents was similar in both groups, except for insulin and sulfonylureas, which were more frequently prescribed in the non-durability group. In multiple logistic regression analyses, higher levels of education, physical activity, and homeostasis model assessment of β-cell function (HOMA-β) were associated with glycemic durability. Notably, lower HbA1c (<7.0%) at baseline and first follow-up were significantly associated with glycemic durability (adjusted odds ratio [OR], 7.48; 95% confidence interval [CI], 2.51 to 22.3) (adjusted OR, 9.27; 95% CI, 1.62 to 53.1, respectively), after adjusting for confounding variables including the types of glucose-lowering agents. CONCLUSION: Early achievement of HbA1c level within the glycemic target was a determinant of long-term glycemic durability in new-onset T2DM, as were higher levels of education, physical activity, and HOMA-β.
Body Mass Index ; Confounding Factors (Epidemiology) ; Diabetes Mellitus, Type 2* ; Follow-Up Studies ; Homeostasis ; Humans ; Insulin ; Logistic Models ; Medical Records ; Odds Ratio ; Physical Education and Training ; Retrospective Studies
Body Mass Index ; Confounding Factors (Epidemiology) ; Diabetes Mellitus, Type 2* ; Follow-Up Studies ; Homeostasis ; Humans ; Insulin ; Logistic Models ; Medical Records ; Odds Ratio ; Physical Education and Training ; Retrospective Studies
Diabetes & Metabolism Journal.2017;41(4):275-283. doi:10.4093/dmj.2017.41.4.275
BACKGROUND: Diabetic cardiac autonomic neuropathy (CAN) is one of the important complications of diabetes. It is characterized by reduced heart rate variability (HRV). METHODS: In this randomized, double-blind, placebo-controlled, multicenter trial, 75 patients were randomly assigned to one of two groups. One group (n=41) received α-lipoic acid (ALA) at an oral dose of 600 mg/day for the first 12 weeks and then 1,200 mg/day for the next 12 weeks. The other group (n=34) received placebo treatment for 24 weeks. CAN was assessed by measuring HRVs in people with diabetes. RESULTS: Most of the baseline measures for HRVs were similar between the ALA and placebo groups. Although there were no statistically significant HRV changes in the ALA group compared to the placebo group after 24 weeks of trial, we found a positive tendency in some of the HRV parameters of the ALA group. The standard deviations of normal-to-normal RR intervals in the standing position increased by 1.87 ms in the ALA group but decreased by −3.97 ms in the placebo group (P=0.06). The power spectrum of the low frequency (LF) band in the standing position increased by 15.77 ms² in the ALA group, whereas it declined by −15.04 ms² in the placebo group (P=0.08). The high frequency/LF ratio in the upright position increased by 0.35 in the ALA group, whereas it declined by −0.42 in the placebo group (P=0.06). There were no differences between the two groups regarding rates of adverse events. CONCLUSION: Although a slight improvement tendency was seen in HRV in the ALA group, there were no statistically significant HRV changes in the ALA group compared to the placebo group after 24 weeks of trial. However, the high oral dose of ALA was well-tolerated.
Diabetes Mellitus, Type 2* ; Heart Rate* ; Heart* ; Humans ; Korea* ; Multicenter Studies as Topic ; Posture ; Thioctic Acid
Diabetes Mellitus, Type 2* ; Heart Rate* ; Heart* ; Humans ; Korea* ; Multicenter Studies as Topic ; Posture ; Thioctic Acid
Diabetes & Metabolism Journal.2017;41(4):265-274. doi:10.4093/dmj.2017.41.4.265
BACKGROUND: Continuous glucose monitoring (CGM) is reported to be a useful technique, but difficult or inconvenient for some patients and institutions. We are developing a glucose area under the curve (AUC) monitoring system without blood sampling using a minimally invasive interstitial fluid extraction technology (MIET). Here we evaluated the accuracy of interstitial fluid glucose (IG) AUC measured by MIET in patients with diabetes for an extended time interval and the potency of detecting hyperglycemia using CGM data as a reference. METHODS: Thirty-eight inpatients with diabetes undergoing CGM were enrolled. MIET comprised a pretreatment step using a plastic microneedle array and glucose accumulation step with a hydrogel patch, which was placed on two sites from 9:00 AM to 5:00 PM or from 10:00 PM to 6:00 AM. IG AUC was calculated by accumulated glucose extracted by hydrogel patches using sodium ion as standard. RESULTS: A significant correlation was observed between the predicted AUC by MIET and CGM in daytime (r=0.76) and nighttime (r=0.82). The optimal cutoff for the IG AUC value of MIET to predict hyperglycemia over 200 mg/dL measured by CGM for 8 hours was 1,067.3 mg·hr/dL with 88.2% sensitivity and 81.5% specificity. CONCLUSION: We showed that 8-hour IG AUC levels using MIET were valuable in estimating the blood glucose AUC without blood sampling. The results also supported the concept of using this technique for evaluating glucose excursion and for screening hyperglycemia during 8 hours in patients with diabetes at any time of day.
Area Under Curve ; Blood Glucose ; Diabetes Mellitus ; Extracellular Fluid* ; Glucose* ; Humans ; Hydrogel ; Hyperglycemia ; Inpatients ; Mass Screening ; Plastics ; Sensitivity and Specificity ; Sodium
Area Under Curve ; Blood Glucose ; Diabetes Mellitus ; Extracellular Fluid* ; Glucose* ; Humans ; Hydrogel ; Hyperglycemia ; Inpatients ; Mass Screening ; Plastics ; Sensitivity and Specificity ; Sodium
Depression and Mortality in Type 2 Diabetes Mellitus.
Diabetes & Metabolism Journal.2017;41(4):263-264. doi:10.4093/dmj.2017.41.4.263
Diabetes & Metabolism Journal.2017;41(4):251-262. doi:10.4093/dmj.2017.41.4.251
Green tea or green tea extract (GT/GTE) has been demonstrated to reduce insulin resistance and improve glycemic control. However, evidence for this health beneficial effect is inconsistent. This systematic review evaluated the effect of GT/GTE on insulin resistance and glycemic control in people with pre-diabetes/type 2 diabetes mellitus (T2DM). Ovid MEDLINE, Embase, AMED, Web of Science, and the Cochrane Library were searched up to April 2017 for randomised controlled trials of participants with pre-diabetes or T2DM, where the intervention was GT/GTE. Meta-analysis was performed to assess the standardised mean difference (SMD) in biomarkers of insulin resistance and glycemic control between GT/GTE and placebo groups. Six studies (n=382) were pooled into random-effects meta-analysis. Overall, no differences were found between GT/GTE and the placebo for glycosylated hemoglobin (HbA1c: SMD, −0.32; 95% confidence interval [CI], −0.86 to 0.23), homeostatic model assessment for insulin resistance (HOMA-IR: SMD, 0.10; 95% CI, −0.17 to 0.38), fasting insulin (SMD, −0.25; 95% CI, −0.64 to 0.15), and fasting glucose (SMD, −0.10; 95% CI, −0.50 to 0.30). No evidence support the consumption of GT/GTE could reduce the levels of HbA1c, HOMA-IR, fasting insulin, or fasting glucose in people with pre-diabetes/T2DM. However, the studies included were small and of varying quality.
Biomarkers ; Diabetes Mellitus ; Diabetes Mellitus, Type 2* ; Fasting ; Glucose ; Hemoglobin A, Glycosylated ; Insulin Resistance* ; Insulin* ; Tea*
Biomarkers ; Diabetes Mellitus ; Diabetes Mellitus, Type 2* ; Fasting ; Glucose ; Hemoglobin A, Glycosylated ; Insulin Resistance* ; Insulin* ; Tea*
Diabetes & Metabolism Journal.2017;41(4):229-250. doi:10.4093/dmj.2017.41.4.229
The notion that obesity-induced inflammation mediates the development of insulin resistance in animal models and humans has been gaining strong support. It has also been shown that immune cells in local tissues, in particular in visceral adipose tissue, play a major role in the regulation of obesity-induced inflammation. Specifically, obesity increases the numbers and activation of proinflammatory immune cells, including M1 macrophages, neutrophils, Th1 CD4 T cells, and CD8 T cells, while simultaneously suppressing anti-inflammatory cells such as M2 macrophages, CD4 regulatory T cells, regulatory B cells, and eosinophils. Recently, however, new cell types have been shown to participate in the development of obesity-induced inflammation and insulin resistance. Some of these cell types also appear to regulate obesity. These cells are natural killer (NK) cells and innate lymphoid cells (ILCs), which are closely related, and invariant natural killer T (iNKT) cells. It should be noted that, although iNKT cells resemble NK cells in name, they are actually a completely different cell type in terms of their development and functions in immunity and metabolism. In this review, we will focus on the roles that these relatively new players in the metabolism field play in obesity-induced insulin resistance and the regulation of obesity.
B-Lymphocytes, Regulatory ; Diabetes Mellitus, Type 2 ; Eosinophils ; Humans ; Inflammation* ; Insulin Resistance* ; Insulin* ; Intra-Abdominal Fat ; Killer Cells, Natural* ; Lymphocytes ; Macrophages ; Metabolism ; Models, Animal ; Natural Killer T-Cells* ; Neutrophils ; Obesity ; T-Lymphocytes ; T-Lymphocytes, Regulatory
B-Lymphocytes, Regulatory ; Diabetes Mellitus, Type 2 ; Eosinophils ; Humans ; Inflammation* ; Insulin Resistance* ; Insulin* ; Intra-Abdominal Fat ; Killer Cells, Natural* ; Lymphocytes ; Macrophages ; Metabolism ; Models, Animal ; Natural Killer T-Cells* ; Neutrophils ; Obesity ; T-Lymphocytes ; T-Lymphocytes, Regulatory
Country
Republic of Korea
Publisher
Korean Diabetes Association
ElectronicLinks
http://e-sciencecentral.org/journals/127/Editor-in-chief
Abbreviation
Diabetes Metab J
Vernacular Journal Title
ISSN
2233-6079
EISSN
2233-6087
Year Approved
2007
Current Indexing Status
Currently Indexed
Start Year
Description
The aims of the Diabetes & Metabolism Journal are to contribute to the cure of and education about diabetes mellitus, and the advancement of diabetology through the sharing of scientific information on the latest developments in diabetology among members of the Korean Diabetes Association and other international societies. The Journal publishes articles on basic and clinical studies, focusing on areas such as metabolism, epidemiology, pathogenesis, complications, and treatments relevant to diabetes mellitus. It also publishes articles covering obesity and cardiovascular disease. Articles on translational research and timely issues including ubiquitous care or new technology in the management of diabetes and metabolic disorders are welcome.In addition, genome research, meta-analysis, and randomized controlled studies are welcome for publication. Priority is given to studies conducted with Asian diabetic subjects. The prevalence of diabetes mellitus in Asia is increasing rapidly. Korea in particular is experiencing the fastest increase in the prevalence of diabetes mellitus in the world. The editorial board invites articles from international research or clinical study groups. Publication is determined by the editors and peer reviewers, who are experts in their specific fields of diabetology.
Powered by IMICAMS(
备案号: 11010502037788, 京ICP备10218182号-8)